54,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

Psychiatric Pharmacogenetics from concepts to cases is a book written by two authors who are highly distinguished leaders in this cutting edge field. The book gives a synopsis of the history of how the science of pharmacogenetics evolved, how this new science can help address the mounting cost of managing adverse drug events, and explains the physiology of pharmacogenetics - the Cytochrome P450 system. This book is unique in that it is the first of its kind to dedicate a chapter on how adopting pharmacogenetic technology in clinical practice can markedly reduce medico-legal risk, and increase…mehr

Produktbeschreibung
Psychiatric Pharmacogenetics from concepts to cases is a book written by two authors who are highly distinguished leaders in this cutting edge field. The book gives a synopsis of the history of how the science of pharmacogenetics evolved, how this new science can help address the mounting cost of managing adverse drug events, and explains the physiology of pharmacogenetics - the Cytochrome P450 system. This book is unique in that it is the first of its kind to dedicate a chapter on how adopting pharmacogenetic technology in clinical practice can markedly reduce medico-legal risk, and increase quality of care. It also dedicates chapters on the ethics and social impact of this burgeoning technology. Finally, and certainly not least, this book provides fifteen detailed clinical cases selected from clinic and hospital patients. For the busy psychiatric practitioner, this book promises to advance their knowledge and skills by giving them practical information they can employ immediately.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. David Durham is a practicing neuropsychiatrist and a distinguished pharmacogenetics researcher. He completed his post-graduate medical training in psychiatric medicine at the University of Virginia and in neurocognitive electrophysi¬ology at Duke University. He has a Master of Science in Public Health from the University of Kansas Medical Center and completed a research fellowship in ecological genetics at Benedictine College. He is an Assistant Clinical Professor of Psychiatry and Genomics, the current Chair of the Board of Governors of the American College of Neurocognitive Medicine and a clinical consultant to the United States Health and Human Services' IHS division. Dr. Durham is a recipient of the American College of Neurocognitive Medicine's Pioneer Investigator Award. He is a member of the scientific advisory board of Genelex Corporation, as well as the boards of directors of The Mosaic Group, Pangea Scientific LC and the United States Brain Injury Alliance (New Mexico). Dr. Durham has served as an editorial board member, review editor, and peer reviewer for a number of scientific journals and is a member of the American Neuropsychiatric Association, The International Neuropsychiatric Association, the International Society for Pharmacoeconomics and Outcomes Research, and the Clinical Pharmacogenetics Implementation Consortium. He is the former host of 'First Health with Dr. Dave' on Fox News.